Clinical trials: Multiple Sclerosis Subjects
Multiple Sclerosis, Sperm
To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS
This study is designed to assess the effects of a therapeutic dose of arbaclofen extended release (ER) tablets compared with placebo on human sperm concentration, motility, and morphology in male subjects with multiple sclerosis…
- Trial name
- NCT02869425
- Testing
- arbaclofen ER Tablets
- Where
- 2 sites in United States
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis
Natalizumab High Titer Immunogenicity and Safety
The primary objective of the study was to evaluate the immunogenicity of natalizumab (Tysabri®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E) administered intravenously (IV) to participants with…
- Trial name
- NCT00516893
- Testing
- BG00002-E (natalizumab high titer)
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot…
- Trial name
- NCT04121221
- Testing
- GA Depot
- Where
- 112 sites in United States, Belarus and 8 more
- Volunteers
- 1,016 people
- Sponsor
- Mapi Pharma Ltd.
Relapsing-Remitting Multiple Sclerosis
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone supplement (cholecalciferol). Low levels of Vitamin D have been described to be associated with a higher risk of developing Multiple…
- Trial name
- SOLAR (NCT01285401)
- Testing
- VigantOL oil plus interferon beta-1a (Rebif), Interferon beta-1a (Rebif®) alone
- Where
- 38 sites in Austria, Denmark and 10 more
- Volunteers
- 260 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Spasticity in People With Multiple Sclerosis
Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis
Phase II a Proof of concept study in Multiple Sclerosis (MS) patients with spasticity.
- Trial name
- NCT02542787
- Testing
- VSN16R
- Where
- 4 sites in United Kingdom
- Volunteers
- 160 people
- Sponsor
- Canbex Therapeutics Ltd
Relapsing-remitting Multiple Sclerosis (RRMS)
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).
- Trial name
- NCT06700343
- Testing
- Ocrelizumab (US), Ocrelizumab (EU), ABP 692
- Where
- 109 sites in United States, Belgium and 20 more
- Volunteers
- 152 people
- Sponsor
- Amgen
Multiple Sclerosis
Task-oriented Circuit Class Training in Multiple Sclerosis Subjects
Aims of the study: This is a single blind randomized-controlled trial to test the feasibility and the effects of a task oriented training on locomotor function, mobility and balance in multiple sclerosis subjects with moderate…
- Trial name
- NCT01464749
- Testing
- Task-oriented circuit class training, usual care
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- University Hospital of Ferrara
Multiple Sclerosis
Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects
Primary Objective: To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-SAR442168.
- Trial name
- NCT04171310
- Testing
- SAR442168
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS.
- Trial name
- NCT02045732
- Testing
- PF-06342674 0.25 mg/kg, PF-06342674 1.5 mg/kg, PF-06342674 6.0 mg/kg
- Where
- 8 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Multiple Sclerosis
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
The primary objective is to determine whether prolonged-release fampridine (10 mg twice daily) has a clinically meaningful effect on participant-reported walking ability over a 24-week study period.
- Trial name
- ENHANCE (NCT02219932)
- Testing
- fampridine
- Where
- 87 sites in United States, Bulgaria and 9 more
- Volunteers
- 646 people
- Sponsor
- Biogen
Secondary Progressive Multiple Sclerosis
Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
This is a prospective, randomized, multicenter, dose escalation study to determine subject safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS
- Trial name
- NCT01181089
- Testing
- Baminercept
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
The primary objective of the study is to evaluate the effect of BG00012 on lymphocyte subset counts during the first year of treatment in subjects with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT02525874
- Testing
- dimethyl fumarate
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 218 people
- Sponsor
- Biogen
Multiple Sclerosis
Safety and Dose-finding Study of DC-TAB in Healthy Subjects
The purpose of this study is to determine safety and appropriate dose of DC-TAB for selective immune tolerance induction in humans.
- Trial name
- NCT02442557
- Testing
- recombinant human alpha B-crystallin
- Where
- Netherlands
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Delta Crystallon BV
Relapse Remitting Multiple Sclerosis
Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
This study investigates the add-on effect of oral minocycline in subjects treated with daily injection of Copaxone. Copaxone and minocycline are thought to have differential modes of actions that may complement each other in…
- Trial name
- NCT00203112
- Testing
- glatiramer acetate with minocycline
- Volunteers
- 44 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Neuropathic Pain, Multiple Sclerosis
Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis
The purpose of this study is to determine whether nabilone (Cesamet) when used as an adjunctive agent with gabapentin (Neurontin) provides significantly improved pain relief over gabapentin alone for the management of neuropathic…
- Trial name
- NCT00480181
- Testing
- nabilone
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Manitoba
Relapsing Multiple Sclerosis
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
- Trial name
- ARTIOS (NCT04353492)
- Testing
- Ofatumumab
- Where
- 123 sites in United States, Argentina and 25 more
- Volunteers
- 562 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Sclerosis
A Study of KHK4827 in Patients With Systemic Sclerosis
Exploratory evaluation of pharmacokinetics and safety of KHK4827 in subjects with systemic sclerosis
- Trial name
- NCT04368403
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Relapsing Remitting Multiple Sclerosis
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg).
- Trial name
- SURPASS (NCT01058005)
- Testing
- BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 84 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis
This is a 1 year study to evaluate the efficacy, safety, and tolerability of Tovaxin T cell therapy in subjects with a clinically isolated syndrome (CIS) and relapse-remitting multiple sclerosis (RR-MS).
- Trial name
- TERMS (NCT00245622)
- Testing
- Tovaxin Autologous T cell vaccine
- Where
- 33 sites in United States
- Volunteers
- 150 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06138132
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University